Microglia underlie amyloid-β clearance in immunized people with Alzheimer disease

IF 28.2 1区医学 Q1 CLINICAL NEUROLOGY

Nature Reviews Neurology Pub Date : 2025-04-10 DOI:10.1038/s41582-025-01084-9

Lisa Kiani

引用次数: 0

Abstract

A study published in Nature Medicine has found that microglia are responsible for amyloid-β (Aβ) clearance in people with Alzheimer disease (AD) treated with Aβ immunotherapies.

Transcriptomic analysis of frontal cortex sections revealed brain region-specific differential expression of genes involved in microglial function in people with AD treated with active Aβ immunotherapy AN1792, as compared with untreated individuals. Established AD risk genes that are involved in the microglial response, including TREM2 and APOE, were among the upregulated genes in treated individuals, and their expression correlated positively with Aβ removal. Similar results were observed in one individual treated with the approved monoclonal antibody lecanamab.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Neurology 医学-临床神经学

CiteScore

29.90

自引率

0.80%

发文量

138

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Neurology aims to be the premier source of reviews and commentaries for the scientific and clinical communities we serve. We want to provide an unparalleled service to authors, referees, and readers, and we work hard to maximize the usefulness and impact of each article. The journal publishes Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives relevant to researchers and clinicians working in the field of neurology. Our broad scope ensures that the work we publish reaches the widest possible audience. Our articles are authoritative, accessible, and enhanced with clearly understandable figures, tables, and other display items. This page gives more detail about the aims and scope of the journal.